IDEAYA Biosciences, Inc. $IDYA Stake Boosted by Fiera Capital Corp

Fiera Capital Corp grew its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 32.6% during the 4th quarter, HoldingsChannel reports. The fund owned 2,437,262 shares of the company’s stock after acquiring an additional 599,295 shares during the period. Fiera Capital Corp’s holdings in IDEAYA Biosciences were worth $84,256,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of IDEAYA Biosciences by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after acquiring an additional 97,116 shares in the last quarter. Baker BROS. Advisors LP grew its holdings in shares of IDEAYA Biosciences by 54.6% during the 3rd quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock valued at $89,125,000 after acquiring an additional 1,156,716 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of IDEAYA Biosciences by 43.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,770,866 shares of the company’s stock valued at $61,219,000 after acquiring an additional 537,753 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of IDEAYA Biosciences by 4.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock valued at $26,025,000 after acquiring an additional 50,000 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of IDEAYA Biosciences by 2.7% during the 4th quarter. UBS Group AG now owns 1,085,632 shares of the company’s stock valued at $37,530,000 after acquiring an additional 29,055 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

IDYA stock opened at $28.29 on Monday. IDEAYA Biosciences, Inc. has a 1 year low of $20.50 and a 1 year high of $39.28. The company has a fifty day simple moving average of $30.19 and a 200 day simple moving average of $32.64. The firm has a market cap of $2.49 billion, a PE ratio of -17.68 and a beta of -0.04.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the firm posted ($0.82) earnings per share. The company’s revenue was down 39.4% compared to the same quarter last year. As a group, analysts forecast that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a report on Monday, April 13th. Royal Bank Of Canada lifted their price objective on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Wells Fargo & Company lifted their price objective on shares of IDEAYA Biosciences from $44.00 to $48.00 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of IDEAYA Biosciences in a research note on Friday, May 22nd. Finally, Mizuho reduced their price objective on shares of IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Fifteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.